由于销售下降、专利到期和竞争加剧,新泽西的毒品制造商削减了就业机会。 New Jersey drugmakers cut jobs due to falling sales, patent expirations, and rising competition.

新泽西的主要制药公司,包括布里斯托尔·迈尔斯·斯基布和默克,在销售下降和关键药品专利即将到期的同时,正在裁员。 Major pharmaceutical companies in New Jersey, including Bristol Myers Squibb and Merck, are cutting jobs amid declining sales and looming patent expirations for key drugs. 布里斯托尔·迈尔斯·斯奎布(Bristol Myers Squibb)的Eliquis面临激烈的竞争和深度折扣,而其他产品则在饱和的市场中挣扎。 Bristol Myers Squibb’s Eliquis faces fierce competition and deep discounts, while other products struggle in saturated markets. Merck在中国的Gardasil需求下降, 并面临2028年专利到期, Merck is seeing reduced Gardasil demand in China and faces a 2028 patent expiry for its top-selling cancer drug Keytruda. 尽管公司引用了结构调整,但分析家们说,裁员反映了来自生物相似、价格竞争和全球需求变化的更广泛的工业压力,影响到数千个高薪工作。 Though companies cite restructuring, analysts say layoffs reflect broader industry pressures from biosimilars, pricing competition, and shifting global demand, impacting thousands of high-paying jobs.